Gilead Sciences Inc

Gilead Sciences (GILD) has a high free cash flow yield of 7.1%, significantly above the S&P 500 median, suggesting it may be undervalued or expected to shrink. While its strong cash flow is largely driven by its HIV drug Biktarvy and high operating margins, investors may be overlooking it due to concerns about its reliance on HIV treatments and declining sales in other segments like Veklury and cell therapy. The company is actively diversifying through acquisitions and has raised its forecast for 2026 HIV sales growth, making its full-year results crucial for addressing investor concerns.

Amgen's stock is trading at EUR 371.30, marking a 29.0 percent increase year-to-date. The stock experienced a 3.12 percent rise on October 9, 2026, reaching EUR 371.30 at Lang & Schwarz, while its Nasdaq price was USD 415.95. Cantor Fitzgerald has raised its target price for Amgen from USD 400.00 to USD 440.00, maintaining a Neutral rating.

GSK stock traded at EUR 20.81 on October 9, 2026, marking a 0.24% increase from its previous close. The company's market capitalization stands at USD 93.2 billion with a P/E ratio of 14.81. Investors are anticipating GSK's next results release scheduled for October 28, 2026.

ImmunityBio is gaining attention after presenting new immunotherapy data at a rare cancer symposium and continuing its involvement in a cancer-care initiative. The company's investment narrative centers on expanding its immunotherapy platform beyond bladder cancer, with a key short-term catalyst being the FDA decision on Anktiva's label expansion in January 2027. Despite a current net loss, analysts project significant revenue growth and a swing to profitability by 2029, suggesting a potential 31% upside to its current stock price.

RBC Capital Markets has raised its price target for Gilead Sciences (GILD) stock from USD 123.00 to USD 126.00, maintaining a Sector Perform rating. This adjustment follows Gilead's strong second-quarter 2026 revenue of USD 7.80 billion, which surpassed the USD 7.40 billion consensus. The company also increased its full-year 2026 HIV growth guidance, indicating robust performance in this segment.

This "Rx Rundown" article details significant medical marketing news, dealmaking, and industry chatter from the past week. It covers major acquisitions and partnerships, including McKesson's acquisition of Option Care Health and Viatris's plan to acquire Pacira Biosciences. The report also highlights recent FDA approvals for various drugs and medical devices, major funding rounds for biotech companies, and notable layoffs within the pharmaceutical and biotech sectors, such as the shutdown of Caribou Biosciences.

Gilead Sciences reported a strong Q2 with revenue up 10.2% year-on-year and full-year EPS guidance above analyst estimates, alongside extending a five-year DevOps and agentic AI partnership with Cognizant. This performance and technology agreement highlight management's focus on current execution and long-term operational efficiency. The article discusses how these factors might influence Gilead's investment narrative, particularly concerning its dependence on HIV products versus growth in oncology and immunology.

Nurix Therapeutics (NRIX) has begun a new Phase 1b/2 clinical trial for chronic lymphocytic leukemia, pairing its BTK degrader bexobrutideg with venetoclax, as part of its collaboration with Roche. Despite recent stock volatility with a 15.0% dip over the past month, the company shows strong year-to-date and annual returns. The article explores whether the current 11% discount to its estimated fair value of $25.00 is justified given ambitious growth plans and potential risks associated with new immunology and neurology programs.

This article provides an overview of Q2 earnings for several therapeutics companies, highlighting Gilead Sciences' strong performance with a 10.2% year-on-year revenue increase and a beat on analysts' expectations. It also discusses Biogen's impressive quarter and contrasts these with Myriad Genetics' disappointing results. The article touches on broader market themes, including the impact of AI and geopolitics on investor sentiment.

Vertex Pharmaceuticals stock was trading at EUR 449.93 with a market capitalization of USD 128.1 billion on October 8, 2026. This represents a slight decrease of 0.38% from its prior close, and the stock is 9.90% below its 52-week high. Analysts have assigned a "Buy" rating with a price target of USD 665.00, and the company is scheduled to report its third-quarter 2026 financial results on November 2, 2026.